Hot Investor Mandate: Taiwan VC Firm Invests in USA & Taiwan-Based Early-Stage Medical Devices, Diagnostics, and Digital Health Companies

An early-stage venture capital firm based in Taiwan was formed by a group of successful entrepreneurs. The firm specializes in incubation, seed and early venture investments in technology-heavy sectors. The firm is currently investing from its latest fund that closed in 2016. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firms open to either leading a financing round or joining a syndication. The firm is currently seeking opportunities from USA and Taiwan.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company for projects they led.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Western Europe VC Firm Actively Seeks Investment Opportunities in USA & Europe-Based Therapeutics, Devices, Diagnostics Companies

A venture capital firm based in Western Europe is investing from its most recent fund closed in 2016. The firm makes equity investments in life sciences and biomedical technology companies at all stages of development. However, the firm prefers late stage preclinical or early stage clinical for therapeutics and diagnostics and medical devices that are close to market approval. The typical investment per round is €4M to €10M. The firm looks for companies that are based in the US, Canada, Israel, and Europe. The firm is actively screening new investment opportunities.

The firm is generally opportunistic in the life sciences space. The firm targets therapeutics and diagnostics, medical devices, and biopharmaceuticals. In therapeutics, the firm focuses on drug development and is open to all indications including orphan indications. In medical devices, the firm has a special focus on interventional devices in cardiology, gastroenterology and pulmonology that are close to or on the market approval. However, the firm is equally opportunistic in other subsectors and indications for medical devices, but all with a therapeutic focus.

The firm invests in companies at all stages of their development. For drug development, the firm invests from late preclinical to mid-stage clinical development. The firm sometimes considers companies with products on the market. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Japan PE Firm Seeks New Investment Opportunities with Strongest Interest in Therapeutics, Devices, Digital Therapeutics

A private equity firm based in headquartered in Japan has a typical investment size of USD 3-5 million per company. The firm’s geographical focus is Asia, but may consider companies in the US and Europe. The firm is actively seeking new investment opportunities.

In the life sciences, the firm will primarily focus on therapeutics, and is also interested in medical devices and digital medicine.  The firm is interested in new technologies such as cell and gene therapies, but also considers investing in small molecules and biologics, as well as biosimilars and reformulated drugs. The firm will invest in any indication area, and invests in companies from the late preclinical stage through to Phase II.

The firm is usually a follow-on investor.  For early stage opportunities, the firm prefers that the company has a clinical trial plan in place.  While the firm is interested in international opportunities, they prefer that the company is interested in expanding into Japan or Taiwan.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Congratulations to our Digital RESI “Europe” Innovation Challenge Winners!

By Claire Jeong, Vice President of Investor Research, Asia BD, LSN

claireOur 3-day digital RESI “Europe” event came to an end yesterday, and we are very excited to announce the Top 3 Winners of the Innovation Challenge. This was a very special Innovation Challenge for the RESI team as all of the poster presentations were held in digital format, with each finalist company having a dedicated page where you could view their poster, short pitch, and other supplementary materials that the companies made available for viewing.

We will keep our RESI Europe “live agenda” page open to the public for another month, so if you have not had the chance already, please visit Digital RESI Europe Live Agenda to see our virtual exhibit of some amazing technologies across therapeutics, medical devices, diagnostics, and digital health!

We would like to thank every Innovation Challenge company for quickly adapting to our digital transition, and we hope that all companies were able to make the most out of the digitally presented Innovation Challenge.

Congratulations to the Top 3 winners, and thank you all for casting your votes!

First Place: Cerebriu A/S

Click Here to Check Out Cerebriu’s Digital Poster

Cerebriu is dedicated to improving workflow efficiency, quality and patient outcomes in diagnostic imaging.

Our software solution Cerebriu Apollo achieves this by automating image acquisition protocols and triage during MRI brain acquisition providing decision support at key stages of the diagnostic process. We offer workflow efficiency gains that result in improved productivity, better use of resources, and prioritization of the patients who need it most.

Initial focus is brain, namely tumors, haemorrhage and infarcts. Future roadmap expands to additional pathologies, body parts and advanced integration with hospital systems.

Second Place: MOWOOT

Click Here to Check Out MOWOOT’s Digital Poster

MOWOOT is a growth stage medical device company targeting intestinal transit disorders with a purely physical, non-drug, non-invasive solution.

MOWOOT offers a CE certified (Med.Dev. class IIa), IP protected, clinically validated and award-winning technology: the first Intermittent Colonic Exo-peristalsis (ICE) device on the market handling a large unmet need for patients with Neurogenic-Bowel-Disorders (NBD), Idiopathic Chronic Constipation (ICC) and Opioid-Induced-Constipation (OIC).

The Global Market for the indication “chronic constipation” alone has an annual worth of US$ 12.58 bn, with a healthy CAGR of 7.1%, estimated to reach US$ 22,93 bn by 2025.

Third Place: Injeq Oy

Click Here to Check Out Injeq’s Digital Poster

IQ-Needle is a hypodermic needle which can tell where its tip is. This makes demanding blind punctures, such as spinal tap, much easier and safer for the patient. Technology is based on measuring the impedance of the tissue the tip is touching using proprietary stylet design, allowing the needle bosy and styulet to be used as electronic measurement probes. IQ-Needle and Analyzer are in pre-production as we are finalizing clinical trials and starting the CE certification process with TÜV SÜD in Germany.

LSN Pivots Again: To Accommodate Early-Stage Life Science Fundraising CEOs and Investment Partners

By Gregory Mannix, Chief Conference Officer, Vice President International Business Development, LSN

After a record breaking Digital RESI Conference in March, replacing the RESI Europe 2020 on-site event, LSN now announces one new Digital RESI, 2-day, dedicated partnering event, taking place April 29th and 30th,  a new Digital RESI event June 8th-10th, replacing on-site RESI, San Diego and, last but not least, Boston RESI On-site September 21st at the Boston Marriott Copley Place.

The feedback from LSN’s Investment, partnering and entrepreneurial networks made this move obvious, as new fresh alternatives are needed to keep the bench to bedside technology assets flowing in the right direction. The main issue with raising early stage capital is that it is a numbers game and entrepreneurs need to regularly work their pipeline of investment partners. The fact that Digital RESI proved that the virtual model works means that LSN can now offer one dedicated Digital partnering event in April, a Digital RESI three day event in June plus the on-site, Boston RESI in September. Interested investors can contact us for a complimentary pass to all of these events here: research@lifesciencenation.com

LSN is also offering a discounted packaged deal which is a much needed solution for engaging with global investment partners on regular basis. LSN will also be giving a free copy of the Life Science Entrepreneurs Fundraising Manifesto with each registration.  This book outlines how to prepare your branding and messaging, how to set up a CRM for keeping track of your Global Target List of investment partners and goes into the detail of both phone and email canvassing for setting up meetings.  LSN is convinced that this package will be a game changer in these coming months for all the global fundraising entrepreneur community.

Digital RESI in Numbers

By Karen Deyo, Senior Investor Research Analyst, LSN

Digital RESI was an idea that arose under unusual circumstances, to say the least. As RESI drew near, we were overwhelmed with the positive responses we received to the change, and our attempt to move forward with an alternative to the traditional on-site conference. Now that the first Digital RESI is behind us, what do the numbers say?

With about 550 attendees, we saw over 1200 meetings taking place over the 3 days of partnering. Below you can find the breakdown of attendees and meetings. With 70% of the meetings taking place between companies and investors, this goes to show that investors are still hungry for good investments, despite the current environment. And while coordinating across time zones is extremely difficult, over 85% of the meetings took place as scheduled.

The proof is in the numbers – digital conferences are providing a way for startups and investors to meet and form relationships with a virtual one-on-one meeting. Make sure to check out the future digital events we will be holding to help make it through the coming months!

Important Information about Digital RESI Partnering

By Karen Deyo, Senior Investor Research Analyst, LSN

Thank you for participating in the first-ever Digital RESI. We want to make sure that this event is a success for you, and the following information will help you use the partnering platform to best advantage in this virtual conference.

First, please note that all currently scheduled meetings take place in Paris local time (CET). Please be aware that you can block off time slots so that you are not getting scheduled by the system at a time that is inconvenient due to your local time zone. The good news is, if you have accepted some meetings, you can reschedule your meetings to a more convenient time.

This is one of the challenges in going from a physical to a global digital format and LSN wants to make sure that all the meetings you book will work for both parties. Also, LSN does recommend making sure you have exchanged phone numbers with the other person, so that if something does happen you can just call the person directly.

Depending on your location, this would mean that the partnering slots take place at:

San Francisco (PST) 12AM-12PM
New York (EST) 3AM-3PM
Paris (CET) 8AM-8PM
Shanghai 3PM-3AM

Digital RESI is giving us an opportunity to continue with LSN’s mission to connect early stage companies with investors and strategic partners who are a fit for them, and we urge all of you to take full advantage of the partnering platform by accepting meetings over the three days of partnering. Virtual partnering meetings will start in 5 short days – make sure to fill your schedule!